← Back to Search

Rucaparib for Ovarian Cancer (CATCH-R Trial)

Phase 3
Waitlist Available
Research Sponsored by ppharmaand GmbH
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline up to approximately 3 years
Awards & highlights

CATCH-R Trial Summary

This trial is for patients who are already benefiting from the drug rucaparib and want to continue treatment. Patients from a related study can also enroll to continue collecting data.

Eligible Conditions
  • Ovarian Cancer
  • Peritoneal Neoplasm
  • Solid Tumors
  • Prostate Cancer

CATCH-R Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline up to approximately 3 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline up to approximately 3 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Safety follow-up

Side effects data

From 2022 Phase 3 trial • 564 Patients • NCT01968213
76%
Nausea
70%
Combined Asthenia/Fatigue
52%
Fatigue
39%
Combined Anaemia and/or decreased hemoglobin
38%
Constipation
38%
Vomiting
37%
Anaemia
35%
Diarrhoea
35%
Alanine aminotransferase increased
34%
Combined ALT/AST increased
33%
Abdominal pain
31%
Dysgeusia
29%
Combined Thrombocytopenia and/or decreased platelets
27%
Aspartate aminotransferase increased
25%
Decreased appetite
23%
Asthenia
22%
Arthralgia
20%
Headache
19%
Combined Neutropenia and/or decreased ANC
19%
Photosensitivity reaction
18%
Cough
17%
Thrombocytopenia
17%
Blood creatinine increased
16%
Dyspepsia
16%
Insomnia
16%
Dizziness
15%
Rash
15%
Pruritus
15%
Dyspnoea
15%
Abdominal pain upper
15%
Back pain
15%
Pyrexia
14%
Platelet count decreased
14%
Neutropenia
13%
Abdominal distension
13%
Upper respiratory tract infection
12%
Hypertension
12%
Oedema peripheral
12%
Hypomagnesaemia
10%
Nasopharyngitis
10%
Alopecia
10%
Taste disorder
10%
Dry skin
10%
Urinary tract infection
9%
Mucosal inflammation
9%
Influenza
9%
Depression
9%
Stomatitis
9%
Erythema
8%
Neutrophil count decreased
8%
Anxiety
8%
Hypercholesterolaemia
8%
Dry mouth
8%
Weight decreased
7%
Myalgia
7%
Oropharyngeal pain
7%
White blood cell count decreased
6%
Gastrooesophageal reflux disease
6%
Influenza like illness
6%
Hot flush
6%
Neck pain
6%
Pain in extremity
6%
Blood alkaline phosphatase increased
5%
Muscle spasms
5%
Sinusitis
5%
Combined Anemia and/or low hemoglobin
1%
Incarcerated hernia
1%
General physical health deterioration
1%
Intestinal obstruction
1%
Sepsis
1%
Muscular weakness
1%
Combined Thrombocytopenia and/or low platelets
1%
Osteoarthritis
1%
Gastrointestinal pain
1%
Pulmonary embolism
1%
Febrile neutropenia
1%
Pancytopenia
1%
Small intestinal obstruction
1%
Dehydration
1%
Combined Netropenia and/or low ANC
1%
Malignant melanoma
1%
Malignant neoplasm progression
1%
Myelodysplastic syndrome
1%
Seizure
1%
Acute kidney injury
1%
Renal failure
100%
80%
60%
40%
20%
0%
Study treatment Arm
Rucaparib 600 mg Tablets
Placebo Tablets

CATCH-R Trial Design

1Treatment groups
Experimental Treatment
Group I: RucaparibExperimental Treatment1 Intervention
Rucaparib administered at dose and schedule last taken in parent study, or per investigator decision
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Rucaparib
2016
Completed Phase 3
~1990

Find a Location

Who is running the clinical trial?

ppharmaand GmbHLead Sponsor
11 Previous Clinical Trials
1,730 Total Patients Enrolled
1 Trials studying Ovarian Cancer
25 Patients Enrolled for Ovarian Cancer
zr Pharma & GmbHLead Sponsor
20 Previous Clinical Trials
4,058 Total Patients Enrolled
5 Trials studying Ovarian Cancer
1,565 Patients Enrolled for Ovarian Cancer
pharmaand GmbHLead Sponsor
21 Previous Clinical Trials
4,141 Total Patients Enrolled
5 Trials studying Ovarian Cancer
1,565 Patients Enrolled for Ovarian Cancer

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there other precedents for this Rucaparib research?

"Rucaparib was first studied in 2014 at Sourasky Medical Center. As of now, there are 15 completed studies and 35 active ones. A notable concentration of these active studies are based in Lakewood, Colorado."

Answered by AI

Are people with the required medical conditions still able to join this experiment?

"Unfortunately, this particular study is not currently enrolling new patients. Although, it's worth mentioning that there are 766 clinical trials for carcinoma and 35 trials for Rucaparib currently recruiting patients."

Answered by AI

Has Rucaparib been cleared by the FDA?

"There is pre-existing evidence suggesting that Rucaparib is safe for human use, so it was given a 3."

Answered by AI

How many people have been or will be enrolled in this trial?

"Recruitment for this clinical trial has closed. The first posting was on March 22nd, 2021 with the most recent edit on January 18th, 2022. There are currently 766 other trials for carcinoma and 35 for Rucaparib that are admitting patients."

Answered by AI

Does this city have more than one research center conducting this clinical trial?

"There are presently 6 sites running this trial, with locations in Lakewood, Sherbrooke, and London, amongst others. If you enroll in this trial, it is best to attend the site nearest you to avoid travel."

Answered by AI

Has a similar study been done before?

"Rucaparib has had 35 clinical trials since the first one in 2014. The first, sponsored by Clovis Oncology, Inc., was a Phase 3 drug approval stage that involved 564 patients and completed in the same year. Since then, there have been 15 more completed trials."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
CATCH-R: A Rollover Study to Provide Continued Access to Rucaparib
2021. "CATCH-R: A Rollover Study to Provide Continued Access to Rucaparib". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04676334.
~8 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top